TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Proclara Biosciences Stock

Proclara Biosciences Stock

proclarabio.comHealthcareFounded: 2006Funding to Date: $112.79MM

Developer of disease-modifying therapies intended to be used for the treatment of neurodegenerative diseases. The company's therapies develop novel therapies that recognize and target multiple misfolded proteins, enabling clinicians to make a transformative impact on the lives of patients affected by Alzheimer's, Parkinson's and systemic amyloidosis.

Buy or sell Proclara Biosciences stockLearn more about Proclara Biosciences IPO
Register for Details

For more details on financing and valuation for Proclara Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Proclara Biosciences.

Register Today

Team

Management Team

Hampus Hillerstrom
Executive Vice President, Co-Founder & Chief Financial Officer
David Michelson MD
Chief Medical Officer & Board Member
Beka Solomon Ph.D
Scientific Founder & Member, Scientific Advisory Board
Jonathan Solomon
Co-Founder and Board Member
Richard Fisher
Chief Executive Officer, President & Board Member

Board Members

David Michelson MD
Jonathan Solomon
Nick Leschly
Paul Goldenheim MD
Valérie Calenda Ph.D
Mérieux Développement
François Valencony
Mérieux Développement
Franz Hefti Ph.D
Kenneth Buckfire
Peter Smedvig
Saira Ramasastry
Daniel Lynch
Hans Schoepflin
Beka Solomon Ph.D
Nico Dosenbach Ph.D
Richard Fisher
Vicki Sato Ph.D

Other companies like Proclara Biosciences in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Cytonics
Sector
Healthcare
 
 
Precision Neuroscience
Sector
Healthcare
 
 

News

FinSMEs 09/09/2016
Proclara Biosciences Secures $47M in Series E Financing |FinSMEs
Proclara Biosciences, a Cambridge, MA-based biotechnology company developing novel therapies for diseases caused by protein misfolding, secured $47m in Series E financing. The round was led by existing investors including private investors and Merieux Developpement. As part of the Series E financing, Daniel Lynch, an experienced biotechnology executive and a venture partner at Third Rock Ventures, …

Trending Companies

Frequently Asked Questions